KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Research & Development: 2010-2025

Historic Research & Development for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to $27.3 million.

  • Nektar Therapeutics' Research & Development fell 22.21% to $27.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.4 million, marking a year-over-year decrease of 4.70%. This contributed to the annual value of $120.9 million for FY2024, which is 5.91% up from last year.
  • Nektar Therapeutics' Research & Development amounted to $27.3 million in Q3 2025, which was down 8.81% from $29.9 million recorded in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' Research & Development peaked at $107.3 million during Q1 2022, and registered a low of $24.1 million during Q3 2023.
  • For the 3-year period, Nektar Therapeutics' Research & Development averaged around $29.3 million, with its median value being $29.7 million (2024).
  • Its Research & Development has fluctuated over the past 5 years, first slumped by 71.59% in 2023, then skyrocketed by 45.54% in 2024.
  • Over the past 5 years, Nektar Therapeutics' Research & Development (Quarterly) stood at $99.6 million in 2021, then tumbled by 65.13% to $34.7 million in 2022, then dropped by 13.81% to $29.9 million in 2023, then dropped by 4.00% to $28.7 million in 2024, then decreased by 22.21% to $27.3 million in 2025.
  • Its last three reported values are $27.3 million in Q3 2025, $29.9 million for Q2 2025, and $30.5 million during Q1 2025.